Due to the incidence of mitral valve regurgitation and mitral valve stenosis on a global scale, by 2026, the mitral valve heart disease in the transcatheter heart valve replacement market will achieve a substantial growth of 23.1%.
PR Newswire-PR Newswire Selbyville, Delaware, USA, January 18, 2021-According to the latest report “Transcatheter Heart Valve Replacement Market by Product (Transcatheter Aortic Valve Replacement, Transcatheter Mitral) Valve repair and replacement, transcatheter pulmonary valve replacement), surgical methods (transfemoral approach, transapical approach), application (aortic valve heart disease, mitral valve heart disease, pulmonary valve heart disease), end-use (hospitals, cath lab), the regional outlook, price trends, competitive market share and forecast 2026 “by: Global market Insights, Inc, 2026, the market value of transcatheter heart valve replacement surgery will be over 19.5 billion. Dollar.
Favorable reimbursement programs in North America and Europe will promote market growth. The Medicare National Coverage Decision is a policy promulgated by Medicare and the Centers for Medicaid Services (CMS) to allow these heart valves to be covered by evidence-backed coverage in the United States. In 2019, CMS updated the Medicare reimbursement policy for transcatheter aortic valves. Replacement (TAVR) program. When surgery is performed in accordance with FDA-approved instructions, the new national coverage policy will continue to cover TAVR with Evidence Development (CED). In addition, Belgium and France provide reimbursements for certain brands, while in other countries, reimbursements for such devices are determined. Only in France, Germany and Switzerland are reimbursements for different types of surgery different. In Germany and Switzerland, the cost of surgery through the apical approach is higher. This reimbursement policy is increasing the number of people receiving the TAVR program.
Request a sample of this research report@ https://www.gminsights.com/request-sample/detail/3170
The growing interest of manufacturers in emerging countries such as the Middle East and Africa will drive the expansion of the transcatheter heart valve replacement market. A large number of different populations in the Middle East and Africa are most affected by cardiovascular disease. Therefore, foreign manufacturers focus on meeting the demand and supply of transcatheter heart valves. The prevalence of aortic valve stenosis in the Middle East has increased the adoption of transcatheter heart valve replacement surgery. Therefore, in the Middle East and Africa, aortic valve manufacturers are seeing huge growth opportunities.
The transcatheter pulmonary valve replacement market segment was valued at more than $537 million in 2019. Transcatheter pulmonary valve replacement is mainly used to treat leaky or stenotic pulmonary valves or patients with potential diagnosis of surgically implanted pulmonary valves. For example, patients with arterial trunks and patients with pulmonary atresia or Ross surgery need to replace the transcatheter pulmonary valve. In addition, the transcatheter pulmonary valve reduces the number of heart surgeries that a patient needs to perform in their lifetime. This factor also contributes to the demand for transcatheter pulmonary valves.
The transapical approach in the transcatheter heart valve replacement market exceeded US$1.16 billion in 2019. The transapical approach is the preferred method because the operator’s proximity to the valve can easily cross the natural valve with the delivery system. This method can also prevent the delivery system from passing around the aortic arch, thereby reducing the risk of stroke in transcatheter aortic valve replacement. In addition, the transapical approach is the method of choice for most healthcare providers because it provides the lowest rate of complications associated with the approach. These factors potentially drive the demand for transcatheter heart valves.
Due to the global incidence of mitral regurgitation and mitral valve stenosis, the transcatheter heart valve replacement market for mitral valve heart disease applications will show a growth rate of more than 23.1% by 2026. According to published articles, more than 4 million people in the United States suffer from mitral regurgitation, and the annual incidence is about 50,000. It is recommended that patients with this condition undergo transcatheter mitral valve replacement. Therefore, the demand for transcatheter heart valves is rapidly increasing. Transcatheter mitral valve replacement devices are undergoing feasibility trials, which will further promote the number of patients undergoing transcatheter mitral valve replacement.
It is estimated that by 2026, the hospital segment in the transcatheter heart valve replacement market will grow at a CAGR of 14.1%. Hospitals will receive favorable reimbursements, which forces patients among other medical institutions to choose hospitals for transcatheter heart valve replacement surgery because of the high cost of these operations. In addition, the government’s increased initiative in the management of valve diseases is another factor in the expansion of the hospital sector.
Brazil dominates the transcatheter heart valve replacement market in Latin America. Driven by the growing elderly population suffering from aortic valve disease, Brazil accounted for US$47 million in 2019. In the past few years, the number of patients with non-rheumatic calcified aortic disease in Brazil has increased significantly. Therefore, in recent years, domestic acceptance of transcatheter heart valve replacement technology has increased, which has led to an increase in the demand and supply of transcatheter heart valves. The rapid increase in the number of hospitals in the country and the strong presence of well-known industry players investing in the development of new transcatheter heart valves have further promoted market demand.
Some of the major companies operating in the transcatheter heart valve replacement market include 4C Medical Technologies, Abbott, Boston Scientific, Edwards Lifesciences, HighLife Medical, JC Medical, LivaNova, Medtronic plc and Neovasc. Industry participants have always focused on the release of innovative products to expand their geographic area and customer base.
Global Market Insights, Inc., headquartered in Delaware, is a global market research and consulting service provider, providing syndicated and customized research reports and growth consulting services. Our business intelligence and industry research reports provide customers with insightful insights and practical market data, which are specially designed and displayed to help strategic decisions. These detailed reports are designed through proprietary research methods and can be used in key industries such as chemistry, advanced materials, technology, renewable energy and biotechnology.
Arun Hegde (Arun Hegde) American Company Sales Global Market Insights Company Phone: 1-302-846-7766 Toll Free: 1-888-689-0688 Email: [Email protected]
transcatheter-heart-valve.png By 2026, the growth rate of the transcatheter heart valve replacement market is expected to be 17.6%: GMI: The major market players in transcatheter heart valve replacement include 4C Medical Technologies, Abbott, Boston Scientific, Edwards Life Science, HighLife Medical, JC Medical, LivaNova, Medtronic plc.
Post time: Jan-19-2021
